Q-omics provides the consensus-scored RAE1 profile across patient tissues and cancer cell-line models. RAE1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RAE1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, RAE1 protein abundance shows 29,855 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LIHC, HNSC, and LSCC as cancer lineages where RAE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAE1 survival associations across molecular data types. RAE1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAE1 RNA expression–survival associations across cancer types. High RAE1 expression shows unfavorable associations in LIHC, MESO, ACC, KICH, LGG and KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RAE1 RNA expression.
This table summarizes RAE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAE1 shows higher tumor expression in HNSC, COAD, BLCA, STAD, LIHC and LUAD. The HNSC box plot shows higher RAE1 RNA expression in tumor versus normal tissue (log2 FC = +1.101, t-test p < 0.001).
This table shows molecular features associated with RAE1 in patient tissues and cancer cell lines. In patient samples, RAE1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
